All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Santhera partners with GEN for AGAMREE distribution in Türkiye; small upfront payment plus sales percentage
Distribution agreement, rare disease, commercialization, milestone payments, Europe - Read more

Pilatus partners with Roche to test PLT012 CD36-targeting antibody with Tecentriq in liver cancer trial
Research collaboration, oncology, antibody, clinical trial, immuno-oncology - Read more

HopeAI partners with Mayo Clinic to develop AI platform for optimizing clinical trial design and reducing drug development costs
Research collaboration, AI/ML, drug discovery, clinical trials, oncology - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps. Half the Budget. Double the Impact.

Stretching your commercial budget?

Get two flex-time reps for the price of one full-time with Promoveo Health.

We build agile field teams that scale up or down based on your brand’s needs — fast.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Response Pharmaceuticals' RDX-002 MTP inhibitor meets Ph2 goals for weight maintenance after GLP-1 discontinuation
Small molecule, metabolic, iMTP inhibitor, obesity, weight management, post-GLP-1 treatment - Read more

Genmab's Ph3 trial: Epcoritamab-R2 combo shows strong efficacy in relapsed follicular lymphoma, FDA priority review underway
Antibody, cancer, bispecific antibody, follicular lymphoma, lymphoma, non-Hodgkin's lymphoma - Read more

RemeGen's telitacicept delivers Ph3 success in Sjögren's syndrome, setting up regulatory filing in China
Protein therapy, autoimmune, fusion protein, Sjögren's syndrome, B-cell target - Read more

Sarepta Therapeutics' Elevidys safety data shows zero deaths among ambulatory Duchenne muscular dystrophy patients
Gene therapy, rare disease, AAV vector, Duchenne muscular dystrophy, liver toxicity, patient stratification - Read more

CytomX resumes Ph1 trial of CX-2051 EpCAM-targeting ADC for colorectal cancer after safety review committee go ahead following reported patient death from treatment-related acute kidney injury
Antibody-drug conjugate, cancer, colorectal cancer, EpCAM target, topoisomerase-1 inhibitor, Phase I - Read more

THE GOOD
Fundraises

Hatteras Venture Partners raises $200M across two funds, investing in early-stage life sciences companies
Venture capital, early-stage, biotech, healthcare - Read more

Compass Therapeutics raises $120M public offering for commercial readiness and clinical development
Oncology, antibody-based therapeutics, biopharmaceutical, clinical-stage - Read more

65LAB awards $1.5M to Duke-NUS platform for antifibrotic drug discovery in lung and kidney diseases
Platform technology, AI-driven, drug discovery, antifibrotic, pulmonary fibrosis, kidney disease - Read more

THE GOOD
Investments

Bionova Scientific opens 10,000-square-foot pDNA facility in Texas to support cell and gene therapy production
Plasmid DNA, gene therapy, strategic expansion, operational, manufacturing - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development & Partnerships

Sarepta Therapeutics sells $174M Arrowhead Pharmaceuticals stock, transfers shares to pay milestone obligation amid cash runway challenges
Equity investment, drug discovery, rare disease, RNAi therapy, milestone payments - Read more

THE BAD
Clinical Trials

Vedanta Biosciences' VE202 bacterial cocktail fails Ph2 trial in ulcerative colitis, showing no symptom improvement
Microbiome therapy, autoimmune, live bacteria, ulcerative colitis, inflammatory bowel disease, gut microbiome - Read more

THE BAD
Company Shutdown

Abata Therapeutics shuts down operations as funding runs short
Autoimmune, cell therapy, Treg therapy, platform technology - Read more [Paywalled]

THE BAD
Layoffs

Oric Pharmaceuticals lays off 20% of workforce to focus on two clinical-stage cancer drugs heading to Phase 3
Small molecule, oncology, strategic, operational, cost reduction - Read more

Merck & Co. begins 8% workforce reduction with 58 layoffs at NJ headquarters, part of $3B cost-cutting plan
Strategic, financial, cost reduction, operational - Read more

Generation Bio cuts 90% of staff as cash concerns threaten clinical development of lipid nanoparticle platform
siRNA lipid nanoparticle, autoimmune, operational, cash constraints - Read more

THE BAD
Market Reports

Biotech IPO drought extends six months since Aardvark Therapeutics' debut, contrasting pandemic-era surge
Financial, strategic, market trends, investment climate - Read more [Paywalled]

THE BAD
Politics & Policy

US tariffs may force Indian generic drugmakers to resume Chinese API dependency, experts warn
Generic drugs, supply chain, strategic, regulatory, competitive - Read more [Paywalled]

THE BAD
Strategic Plans

Autolus Therapeutics delays European sales of newly-approved leukemia cell therapy until 2027 due to market access challenges
CAR-T, oncology, market access, regulatory, financial impact - Read more [Paywalled]

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here